RBS2418 not checked

Riboscience, LLC.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.”In the company’s words, NCT07175441 on ClinicalTrials.gov
Tested for
Advanced Unresectable Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Cancer
Main trialPhase 2
“RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance…”In the company’s words, NCT07175441 on ClinicalTrials.gov

Other drugs for Metastatic Colorectal Cancer

All 392 drugs for Metastatic Colorectal Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Apr 2027 Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Phase 2Recruiting Dec 2027 Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Phase 1Recruiting Apr 2027 Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RBS2418

Following is part of Solo: you see every change to RBS2418 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in